Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland (RETRO-idel)

April 11, 2019 updated by: Gilead Sciences

A Retrospective Observational Study to Evaluate the Clinical Outcomes and Routine Management of Patients With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland

The primary objective of this study is to evaluate the effectiveness of idelalisib and rituximab in adults with chronic lymphocytic leukaemia (CLL) in a real world setting

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

112

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Ireland
      • Dublin, Ireland, 8
        • St James Hospital
  • United Kingdom
      • Aberdeen, United Kingdom, AB25 2ZN
        • NHS Grampian
      • Cardiff, United Kingdom, CF14 4XW
        • University Hospital of Wales
      • Cheltenham, United Kingdom, GL53 7AN
        • Cheltenham General Hospital
      • Eastcote, United Kingdom, HA4 8PD
        • London Northwest University NHS Trust
      • Gillingham, United Kingdom, ME7 5NY
        • Medway Maritime Hospital
      • Harrow, United Kingdom, HA1 3UJ
        • Queen Alexandra Hospital
      • London, United Kingdom, SE5 9RS
        • King's College Hospital NHS Foundation Trust
      • Milton Keynes, United Kingdom, MK6 5LD
        • Milton Keynes University Hospital
      • Oxford, United Kingdom, OX3 7LE
        • Oxford University Hospitals NHS Trust
      • Prescot, United Kingdom, L35 5DR
        • Whiston Hospital - St Helens And Knowsley Teaching Hospitals NHS Trust
      • Southend-On-Sea, United Kingdom, SS0 0RY
        • Southend University Hospital NHS Foundation Trust
      • Sutton, United Kingdom, SM2 5PT
        • Royal Marsden Hospital
      • Swansea, United Kingdom, SA2 8QA
        • Singleton Hospital
      • Truro, United Kingdom, TR1 3LJ
        • Royal Cornwall Hospital
      • Worcester, United Kingdom, WR5 1DD
        • Worcestershire Royal Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Potential study participants will be identified by sites/hospitals as eligible for inclusion in the study by review of hospital records, including prescribing databases and by members of their direct care team and/or site personnel. The study will only include individuals who initiated idelalisib from September 2014, the date of marketing authorisation, up to and inclusive of 31 December 2017.

Description

Inclusion Criteria:

  • Diagnosis of CLL documented within medical records
  • Individuals who have received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation at the time of starting idelalisib treatment
  • Idelalisib and rituximab initiated on or before 31 December 2017

Exclusion Criteria:

  • Individuals who received idelalisib as part of an interventional clinical trial
  • Individuals who received idelalisib for other indications including follicular lymphoma (FL)
  • Individuals who previously received idelalisib in combination with ofatumumab
  • Use of idelalisib which is not in accordance with its marketing authorisation at the time of starting idelalisib treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Idelalisib and Rituximab
Individuals who received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation.
Drug: Idelalisib
Tablets were administered in accordance with the marketing authorization.
Other Names:
  • Zydelig®
Drug: Rituximab
Tablets were administered in accordance with the marketing authorization.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Response Rate
Time Frame: Up to 3 months
Overall Response Rate (ORR) is defined as the proportion of participants who achieve a clinical response as documented within their patient records after the initiation of treatment with idelalisib and rituximab during the observation period.
Up to 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival
Time Frame: Up to 3 months
Overall survival (OS) is defined as the interval from the initiation of idelalisib and rituximab to death from any cause
Up to 3 months
Progression-Free Survival
Time Frame: Up to 3 months
Progression-free survival (PFS) is defined as the interval from the initiation of idelalisib and rituximab to the first documentation of definitive disease progression or death from any cause; definitive disease progression is CLL progression based on documentation in participant records
Up to 3 months
Time to Next Treatment
Time Frame: Up to 3 months
Time to next treatment (TTNT) is defined as the interval from the initiation of treatment with idelalisib and rituximab to the initiation of next treatment
Up to 3 months
Duration of Response
Time Frame: Up to 3 months
Duration of response (DOR) is defined as the interval from the first documentation of clinical response to the earlier of the first documentation of definitive disease progression or death from any cause
Up to 3 months
Overall Safety and Tolerability of Idelalisib and Rituximab as Measured by the Incidence of Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)
Time Frame: Up to 3 months
Up to 3 months
Starting Dose of Idelalisib
Time Frame: Up to 3 months
Up to 3 months
Proportion of Participants with Dose-Modifications, Treatment Interruptions and Discontinuations of Idelalisib
Time Frame: Up to 3 months
Up to 3 months
Proportion of Participants For Whom antibiotic Prophylactic Measures were Effective
Time Frame: Up to 3 months
Up to 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Gilead Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 12, 2018

Primary Completion (Actual)

March 26, 2019

Study Completion (Actual)

March 26, 2019

Study Registration Dates

First Submitted

June 27, 2018

First Submitted That Met QC Criteria

June 27, 2018

First Posted (Actual)

July 10, 2018

Study Record Updates

Last Update Posted (Actual)

April 12, 2019

Last Update Submitted That Met QC Criteria

April 11, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GS-UK-312-4639

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Lymphocytic Leukaemia

Clinical Trials on Idelalisib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe